Straits Times Index
3,290.70 +24.75 (+0.76%) Nikkei
38,229.11 +155.13 (+0.41%) Hang Seng
18,963.68 +425.87 (+2.30%) FTSE 100
8,433.76 +52.41 (+0.63%) Bitcoin USD
60,734.75 -1,812.61 (-2.90%) CMC Crypto 200
1,302.78 -55.23 (-4.07%)
LLY Jan 2025 470.000 call
| Previous close | 323.18 |
| Open | 323.18 |
| Bid | 306.55 |
| Ask | 310.05 |
| Strike | 470.00 |
| Expiry date | 2025-01-17 |
| Day's range | 323.18 - 323.18 |
| Contract range | N/A |
| Volume | |
| Open interest | 266 |
ZacksPharma Stock Roundup: PFE DMD Study Patient Death, FDA Panel Meet for LLY's Donanemab
Pfizer (PFE) reports the death of a participant in a mid-stage study of its Duchenne drug. An FDA panel meeting to discuss Eli Lilly's (LLY) donanemab is set to take place on Jun 10.
ZacksZacks Investment Ideas feature highlights: Eaton, Eli Lilly and Arista Networks
Eaton, Eli Lilly and Arista Networks have been highlighted in this Investment Ideas article.
- Reuters
UPDATE 2-India's Cipla open to partnering with Eli Lilly to market their obesity drugs, CEO says
Cipla is open to partnering with U.S. drugmaker Eli Lilly to market its blockbuster obesity treatment drugs in India, the company's CEO said on Friday. Global demand has outpaced supply for Lilly's Mounjaro and Zepbound as well as Danish rival Novo Nordisk's Wegovy and Ozempic. Sensing the market opportunity, Indian drugmakers, including Cipla, are working to develop their copycat versions of the weight-loss drugs to aggressively grab a larger share in the market in the world's most populous country.
